-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
German pharmaceutical company Merck KGaA, the non-profit research organization IAVI and the Indian Serum Research Institute have collaborated to develop monoclonal antibodies (mAb) for COVID-19.
IAVI, a non-profit research organization, are responsible for identifying monoclonal antibodies from the blood of PATIENTs with COVID-19.
If mAb, developed in partnership with partners, is found to be effective in clinical trials, whether as a single antibody or as a potential combination of two drug candidates, Merck KGaA will commercialize these drugs in developed countries and the Serum Institute of India will commercialize low- and middle-income countries, including India.
an accelerated preclinical and clinical research program will be conducted to evaluate antibodies used to treat COVID-19, in accordance with IAVI's agreements with Merck KGaA and the Indian Serum Research Institute.
phase I clinical trials are expected to begin in early 2021.
Feinberg, President and CEO of IAVI, said, "We are acutely aware of the huge potential of monoclonal antibody therapy COVID-19.
we hope this partnership will provide monoclonal antibodies to patients around the world."
.